Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
About Athenex, Inc.
Sector
Industry
CEO
Yiu Nam Lau
Website
Headquarters
Buffalo
Founded
2003
ISIN
US04685N2027
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Athenex, Inc. stocks are traded under the ticker A3D48T.
Yes, you can track Athenex, Inc. financials in yearly and quarterly reports right on TradingView.
Athenex, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
No, A3D48T doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, A3D48T shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Athenex, Inc. stock right from TradingView charts — choose your broker and connect to your account.